NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
| NXTC Stock | USD 12.60 0.35 2.86% |
About 76 percent of all NextCure's shareholders are aggressively thinking of buying. The analysis of the overall investor sentiment regarding NextCure suggests that quite a large number of traders are excited. The current market sentiment, together with NextCure's historical and current headlines, can help investors time the market. In addition, many technical investors use NextCure stock news signals to limit their universe of possible portfolio assets.
LNCB74 GLP tox studies completed and targeting an IND application by year-endNC410 combo with pembrolizumab ovarian cohort enrollment completedCash of approximately 86.4 million expected to fund operations into second half of 2026 BELTSVILLE, Md., Aug. 01, 2024 -- NextCure, Inc. , a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a busi
Read at finance.yahoo.com
 |
NextCure Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards NextCure can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
NextCure Fundamental Analysis
We analyze NextCure's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NextCure using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NextCure based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
NextCure is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
NextCure Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NextCure stock to make a market-neutral strategy. Peer analysis of NextCure could also be used in its relative valuation, which is a method of valuing NextCure by comparing valuation metrics with similar companies.
Peers
NextCure Related Equities
| CLRB | Cellectar Biosciences | 3.99 | ||||
| ICU | LMF Acquisition | 1.79 | ||||
| DARE | Dare Bioscience | 1.55 | ||||
| CTXR | Citius Pharmaceuticals | 0.64 | ||||
| PULM | Pulmatrix | 0.20 | ||||
| ATHA | Athira Pharma | 0.24 | ||||
| CRIS | Curis | 0.67 | ||||
| PTHS | Pelthos Therapeutics | 0.75 | ||||
| FBLG | FibroBiologics, Common | 2.50 | ||||
| ASBP | Aspire BioPharma, | 2.56 |
Complementary Tools for NextCure Stock analysis
When running NextCure's price analysis, check to measure NextCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCure is operating at the current time. Most of NextCure's value examination focuses on studying past and present price action to predict the probability of NextCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCure's price. Additionally, you may evaluate how the addition of NextCure to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |